About:
Ordaos Bio describes themselves as a human-enabled, machine-driven drug design company. By using generative AI, their proprietary multitask meta-learning and reinforcement learning, Ordaos is creating novel mini-proteins from scratch. Called miniPROTM proteins, Ordaos’ mini-proteins provide the power and performance of antibodies, but are more configurable, stable and easier to manufacture. The technology developed by Ordaos can be used for various indications - through internal programs and pharma and biotech partnerships, Ordaos is delivering safer and more effective therapeutics.